We’re proud to have recently attended the 2024 Northern California Kidney Walk, with Tami Ralston, one of CorMedix's Key Account Managers. A special thanks to the National Kidney Foundation for hosting this impactful event focused on helping accelerate research, enhancing patient services, and providing crucial education and support for those affected by chronic kidney disease.
About us
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The company is focused on developing its lead product DefenCath™, a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. DefenCath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product (QIDP), and the original New Drug Application (NDA) received priority review in recognition of its potential to address an unmet medical need. For more information, visit: www.cormedix.com.
- Website
-
http://www.cormedix.com
External link for Cormedix Inc.
- Industry
- Pharmaceutical Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Berkeley Heights, New Jersey
- Type
- Public Company
- Founded
- 2006
Locations
-
Primary
Get directions
300 Connell Dr
Suite 4200
Berkeley Heights, New Jersey 07922, US
Employees at Cormedix Inc.
-
Alex D.
V.P. Commercial Operations, Marketing & Sales Professional.
-
Lauren D.
HR Leader | Strategic Human Resources Business Partner | Talent Management | Trusted Advisor
-
Philip Williams
Director Supply Chain and IT Implementation
-
Marga Pandey
Finance - Specialized in Gross-to-Net for Pharmaceutical business.
Updates
-
DefenCath® (taurolidine and heparin) is now available for purchase for inpatient and outpatient use through contract on Premier, Vizient, and Renal Purchasing Group. Reach out to your local key account manager and visit www.DefenCath.com for more information.
-
-
We’re pleased to share that the U.S. Food and Drug Administration (FDA) has provided supportive feedback to our plans to pursue a potential label expansion. Learn more: https://lnkd.in/esC_xr9M
-
-
We're excited to be exhibiting at the ASHP Pharmacy Futures Meeting. ASHP’s meeting sets the stage for pharmacy professionals to explore the latest advancements and innovations in healthcare. See you there! #ASHP #PharmacyInnovation
-
-
We’re thrilled to be exhibiting at the Spring Clinical Meeting hosted by the National Kidney Foundation! NKF continues to raise the bar for gathering the brightest minds in #renal health to delve into cutting-edge research and best practices in #nephrology. We’re excited to see you there!
-
-
Today, we announced our 1Q 2024 financial results and provided a business update. Learn more: https://lnkd.in/eRw4S_N2
-
-
During National Nurses Week, we’re proud to honor the unwavering dedication and resilience of nurses. Join us in expressing our sincere gratitude to these exceptional professionals who play a pivotal role in healthcare. #NursesWeek #ANANursesWeek
-
-
Join us at Asembia's AXS24 Summit as we connect with industry leaders across the pharmaceutical supply chain to discuss innovations in patient care. Let's connect at the conference! #AsembiaAXS24
-
-
Today, we announced that the Center for Medicare & Medicaid Services (CMS) has determined that DefenCath® (taurolidine and heparin) meets the criteria for a Transitional Drug Add-On Payment (TDAPA) in the anti-infective functional category, beginning on July 1, 2024. Learn more: https://lnkd.in/esrxYe3a
-
-
At the heart of #nephrology care are the nurses who make it all happen. We’re excited to be exhibiting at the American Nephrology Nurses Association (ANNA) National Symposium and can't wait to connect with the incredible nurses who make a difference in kidney care every day. #ANNA24 #nephrologynurse
-